Daiichi Faces Patent Suit Over New Breast Cancer Drug
Law360 (October 20, 2020, 7:16 PM EDT) -- Daiichi Sankyo is facing claims in Texas federal court that its recently approved breast cancer treatment drug, which has allegedly earned the Japanese pharmaceutical giant $70 million in sales, infringes a U.S. biotechnology company's patent.
Seagen Inc. lodged a complaint on Monday claiming that Daiichi Sankyo Co. Ltd.'s breast cancer treatment medication it markets under the brand name Enhertu infringes a patent covering the delivery of a drug that Seagen sells called Adcetris.
Seagen has been marketing Adcetris since 2011, and the U.S. Food and Drug Administration approved Daiichi Sankyo's Enhertu in January, according to the lawsuit.
Seagen, which had been doing...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!